Aarti Drugs (NSE:AARTIDRUGS) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AARTIDRUGS Aarti Drugs Ltd NSE:AARTIDRUGS
72 GF Score
Price ₹439.35
GF Value ₹506.74
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aarti Drugs Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Aarti Drugs Quality Rank Related Terms

NSE:AARTIDRUGS
72GF Score
Aarti Drugs Ltd NSE:AARTIDRUGS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued. The current stock price of ₹439.35 is trading 13.3% below its estimated GF Value™ of ₹506.74. GuruFocus considers Aarti Drugs to be Modestly Undervalued.

Key valuation signals for NSE:AARTIDRUGS:

  • Quality Rank:
  • GF Value™: ₹506.74 vs. price of ₹439.35 (13.3% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Drugs Business Description

Other Exchanges 524348:India
Address Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
72GF Score

Get the complete analysis for NSE:AARTIDRUGS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹439.35
Price
₹506.74
GF Value